<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21859">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02105012</url>
  </required_header>
  <id_info>
    <org_study_id>PT008001</org_study_id>
    <nct_id>NCT02105012</nct_id>
  </id_info>
  <brief_title>Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma</brief_title>
  <official_title>A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, chronic dosing (4 weeks), four-period, five-treatment,
      incomplete block, cross-over, multicenter study to assess the efficacy and safety of four
      doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult
      subjects with mild to moderate persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in morning pre-dose trough forced expiratory volume in one second (FEV1)</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean morning pre-dose and mean evening pre-dose peak flow rate (PEFR)</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean number of puffs of rescue Ventolin HFA</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Asthma Control Questionnaire (ACQ) score</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in morning pre-dose trough FEV1 over the Treatment Period and at Day 15 and Day 29 of the Treatment Period</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in mean morning and evening pre- and post-dose daily PEFR</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the mean number of puffs of rescue Ventolin HFA</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of days without rescue Ventolin HFA use</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in pre-dose trough forced vital capacity (FVC)</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in pre-dose trough PEFR</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in pre-dose trough forced expiratory flow 25-75% (FEF25-75)</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the number of nighttime awakenings due to asthma symptoms</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of nights with awakenings due to asthma symptoms</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety assessments include ECGs, vital sign measurements, clinical laboratory tests, monitoring for paradoxical bronchospasm, physical examination findings, Adverse Events (AEs) and Serious Adverse Events (SAEs)</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT008 administered as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT008 administered as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT008 administered as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT008 administered as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo MID administered as 2 inhalations BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Inhalation Aerosol (PT008) Dose 1</intervention_name>
    <description>Budesonide Inhalation Aerosol (PT008) administered as 2 inhalations BID</description>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 2</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 3</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Inhalation Aerosol (PT008) Dose 2</intervention_name>
    <description>Budesonide Inhalation Aerosol (PT008) administered as 2 inhalations BID</description>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 1</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 3</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Inhalation Aerosol (PT008) Dose 3</intervention_name>
    <description>Budesonide Inhalation Aerosol (PT008) administered as 2 inhalations BID</description>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 1</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 2</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Inhalation Aerosol (PT008) Dose 4</intervention_name>
    <description>Budesonide Inhalation Aerosol (PT008) administered as 2 inhalations BID</description>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 1</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 2</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 3</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo MDI administered as 2 inhalations BID</description>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 1</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 2</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 3</arm_group_label>
    <arm_group_label>Budesonide Inhalation Aerosol (PT008) Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 - 65 years of age

          -  Diagnosis of mild to moderate persistent asthma, diagnosed at least 6 months prior to
             screening

          -  Currently receiving treatment with a low to medium dose of an ICS OR a combination of
             controller medications for at least 4 weeks preceding screening

          -  Pre-albuterol FEV1 of &gt; 60% and &lt; 85% of predicted normal value

          -  Reversibility: Increase in FEV1 of ≥ 12% and ≥ 200mL over the pre-albuterol FEV1
             within 30 - 60 minutes after the inhalation of 4 puffs of Ventolin HFA

          -  Asthma Symptom Criteria: Have required albuterol use on at least two of the last
             seven days and have an Asthma Control Questionnaire (ACQ) total score ≥ 1.5 prior to
             Randomization

        Exclusion Criteria:

          -  Life-Threatening Asthma: A subject must not have life-threatening asthma defined as a
             history of significant asthma episode(s) requiring intubation associated with
             hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal
             episode(s) within the 12 months prior to screening

          -  Worsening of Asthma: A subject must not have experienced a worsening of asthma which
             involved an emergency department visit, hospitalization or use of oral/parenteral
             corticosteroids within 6 weeks of screening

          -  Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only
             intermittent, seasonal or exercise-induced asthma are excluded from participation in
             this study

          -  Concurrent Respiratory Disease

          -  Pregnant women or nursing mothers

          -  A current diagnosis of Chronic Obstructive Pulmonary Disease (COPD

          -  Current smokers or subjects with a &gt; 10 pack year history of cigarettes, cigars, or
             pipe smoking

          -  Respiratory tract infection within 6 weeks prior to Visit 1

          -  Subjects with documented myocardial infarction within a year from screening visit

          -  Clinically significant abnormal ECG

          -  Abnormal liver function tests defined as aspartate aminotransferase (AST), alanine
             aminotransferace (ALT), alkaline phosphatase or total bilirubin ≥ 1.5 times upper
             limit of normal on repeat testing

          -  Subjects who have cancer that has not been in complete remission for at least 5 years

          -  Drug Allergy: Subjects who have a history of hypersensitivity to any component of the
             MDI
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahid Siddiqui, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Faria</last_name>
    <phone>862-777-8047</phone>
    <email>lfaria@pearltherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pearl Therapeutics</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild</keyword>
  <keyword>moderate persistent</keyword>
  <keyword>Adult</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
